Immune cell therapy takes on stubborn IBD
NCT ID NCT07309744
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with moderate-to-severe ulcerative colitis or Crohn's disease. The study includes up to 30 adults who have not responded well to other treatments. The main goal is to check safety and find the best dose, while also looking at whether it can reduce inflammation and improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.